ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CASI CASI Pharmaceuticals Inc

3.65
0.65 (21.67%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 127,150
Bid Price 3.40
Ask Price 4.00
News (1)
Day High 3.72

Low
1.71

52 Week Range

High
8.48

Day Low 2.95
Company Name Stock Ticker Symbol Market Type
CASI Pharmaceuticals Inc CASI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.65 21.67% 3.65 19:59:59
Open Price Low Price High Price Close Price Prev Close
2.95 2.95 3.72 3.61 3.00
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
824 127,150 $ 3.28 $ 417,178 - 1.71 - 8.48
Last Trade Time Type Quantity Stock Price Currency
19:51:09 formt 150 $ 3.65 USD

CASI Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
48.09M 13.32M - 43.11M -41.01M -3.08 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CASI Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CASI Message Board. Create One! See More Posts on CASI Message Board See More Message Board Posts

Historical CASI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.073.722.92013.0177,9350.5818.89%
1 Month5.756.862.92015.43562,129-2.10-36.52%
3 Months6.558.192.92015.51214,912-2.90-44.27%
6 Months2.368.482.225.48128,0071.2954.66%
1 Year1.818.481.714.8879,4861.84101.66%
3 Years20.2024.201.4512.74599,978-16.55-81.93%
5 Years31.1039.001.4515.77477,095-27.45-88.26%

CASI Pharmaceuticals Description

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

Your Recent History

Delayed Upgrade Clock